AU2018335555A9 - Topical products with a biphasic system - Google Patents
Topical products with a biphasic system Download PDFInfo
- Publication number
- AU2018335555A9 AU2018335555A9 AU2018335555A AU2018335555A AU2018335555A9 AU 2018335555 A9 AU2018335555 A9 AU 2018335555A9 AU 2018335555 A AU2018335555 A AU 2018335555A AU 2018335555 A AU2018335555 A AU 2018335555A AU 2018335555 A9 AU2018335555 A9 AU 2018335555A9
- Authority
- AU
- Australia
- Prior art keywords
- acid
- final concentration
- weight
- present
- topical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002051 biphasic effect Effects 0.000 title claims abstract description 24
- 230000000699 topical effect Effects 0.000 title abstract description 12
- 229940025703 topical product Drugs 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 34
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 24
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 229940099563 lactobionic acid Drugs 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 16
- 229960004889 salicylic acid Drugs 0.000 claims description 16
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 14
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 14
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 14
- 239000011975 tartaric acid Substances 0.000 claims description 14
- 235000002906 tartaric acid Nutrition 0.000 claims description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 239000004264 Petrolatum Substances 0.000 claims description 12
- 229940066842 petrolatum Drugs 0.000 claims description 12
- 235000019271 petrolatum Nutrition 0.000 claims description 12
- 229960004106 citric acid Drugs 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 239000000080 wetting agent Substances 0.000 claims description 10
- 229960001367 tartaric acid Drugs 0.000 claims description 9
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 8
- 229940074928 isopropyl myristate Drugs 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 229960004319 trichloroacetic acid Drugs 0.000 claims description 8
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims description 7
- 230000000975 bioactive effect Effects 0.000 claims description 7
- 229960002887 deanol Drugs 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 150000001261 hydroxy acids Chemical class 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001273 Polyhydroxy acid Polymers 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 235000019192 riboflavin Nutrition 0.000 claims description 6
- 239000002151 riboflavin Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 5
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 5
- 239000003974 emollient agent Substances 0.000 claims description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 4
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 4
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960002591 hydroxyproline Drugs 0.000 claims description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 4
- 238000009736 wetting Methods 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- -1 pH adjusters Substances 0.000 claims description 3
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229920006317 cationic polymer Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 2
- 229960003681 gluconolactone Drugs 0.000 claims description 2
- 229960004275 glycolic acid Drugs 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000006254 rheological additive Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 229940075495 isopropyl palmitate Drugs 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- 239000000047 product Substances 0.000 description 26
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 11
- 239000003381 stabilizer Substances 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 7
- 229940032094 squalane Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 5
- 235000010378 sodium ascorbate Nutrition 0.000 description 5
- 229960005055 sodium ascorbate Drugs 0.000 description 5
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 5
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- SXFBQAMLJMDXOD-UHFFFAOYSA-N (+)-hydrogentartrate bitartrate salt Chemical compound OC(=O)C(O)C(O)C(O)=O.OC(=O)C(O)C(O)C(O)=O SXFBQAMLJMDXOD-UHFFFAOYSA-N 0.000 description 2
- FBVVGPMIPAZFAW-RZVRUWJTSA-N (2S)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H]1CCCN1 FBVVGPMIPAZFAW-RZVRUWJTSA-N 0.000 description 2
- OOGFPFWTORZYAN-AQHGXSAQSA-N (2s,4r)-4-oxidanylpyrrolidine-2-carboxylic acid Chemical compound O[C@H]1CN[C@H](C(O)=O)C1.O[C@H]1CN[C@H](C(O)=O)C1 OOGFPFWTORZYAN-AQHGXSAQSA-N 0.000 description 2
- USQNCFXGTTYZNF-UHFFFAOYSA-N 2,2,2-trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl.OC(=O)C(Cl)(Cl)Cl USQNCFXGTTYZNF-UHFFFAOYSA-N 0.000 description 2
- LPMKADABKPYRHE-UHFFFAOYSA-N 2-aminobutanoic acid Chemical compound CCC(N)C(O)=O.CCC(N)C(O)=O LPMKADABKPYRHE-UHFFFAOYSA-N 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 description 2
- FZIPCQLKPTZZIM-UHFFFAOYSA-N 2-oxidanylpropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FZIPCQLKPTZZIM-UHFFFAOYSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920000289 Polyquaternium Polymers 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003158 myorelaxant agent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- JDQURBODCNMVIO-UHFFFAOYSA-N propan-2-yl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C.CCCCCCCCCCCCCC(=O)OC(C)C JDQURBODCNMVIO-UHFFFAOYSA-N 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 206010012422 Derealisation Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 241000498779 Myristica Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/03—Liquid compositions with two or more distinct layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A biphasic topical product is described, comprising a hydrophilic phase and a lipophilic phase floating on said hydrophilic phase. A method for preparing biphasic topical products is also described.
Description
"TOPICAL PRODUCTS WITH A BIPHASIC SYSTEM" FIELD OF THE INVENTION
The present invention relates to topical products with a biphasic system, as well as to a method for preparing the same.
BACKGROUND ART
In the medical and dermocosmetic field, it is common practice to use acidic substances to exploit the exfoliating activity in skin treatments. These treatments are called chemical peels, from the verb "to peel". Their main action is to rejuvenate the skin and, as a result, promote skin renewal by promoting the removal of the most superficial skin layers through chemical exfoliation. This type of treatment is capable of acting on the skin through the action of different mechanisms, including the stimulation of cellular regeneration (turnover), thus eliminating and exfoliating the dead cells of the horny layer.
Subsequently, the damaged or otherwise degenerated cells are eliminated, which in turn are replaced by epidermal cells. Among the most used substances for chemical peels, there are: trichloroacetic acid, glycolic acid, resorcinol, salicylic acid, pyruvic acid, phenol, mandelic acid, lactic acid, retinoic acid, kojic acid, citric acid, pyruvic acid etc. The action of these treatments depends on the type of acid used, the concentration and chemical stability thereof and also the area of application. Trichloroacetic acid is one of the most widely used substances owing to its marked exfoliating properties.
At the chemical level, it is a carboxylic acid, which at room temperature appears as a crystalline colorless solid with a pungent, strongly hygroscopic and highly oxidizable odor. Trichloroacetic acid has a structure comparable to that of acetic acid to which the three hydrogen atoms have been substituted with three chlorine atoms. This substitution shifts the electronic charge of the "alpha" carbon towards the chlorine atoms, thus
determining a condition of partial electron-deficiency on the above- mentioned carbon, which in turn attracts the electronic charge of the adjacent carbon and therefore of the oxygen, which will tend to divide the proton more significantly if introduced into an aqueous environment, owing to the marked derealization of the negative charge.
The particular electronic organization of the molecule, due to the high negative potential generated by the three chlorine atoms on the carbon in "beta" shifts the electronic balance towards the chlorine atoms and makes the molecule less stable and oxidizable, thus facilitating the cleavage between carbon in alpha and beta, resulting in the formation of formic acid and chloroform, harmful substances, highly irritating and allergenic to the dermis.
The oxidation of trichloroacetic acid is known in the medical field, as it involves the browning of the products containing the same, normally used in the form of monophasic hydro gels, with a relative cleavage of the trichloroacetic acid molecule. The browning of the compound, in addition to the loss of activity of the product, also entails a very significant loss of safety of the product containing trichloroacetic acid, since the latter will no longer contain the trichloroacetic acid as such, but a mixture of trichloroacetic acid, chloroform and formic acid. The mixture will tend to be composed of the latter as the oxidative process completes until the total trichloroacetic acid contained in the product is split.
WO2007/042824A1 describes a composition comprising trichloroacetic acid, alpha-, beta- and polyhydroxy acids, vitamins, amino acids. Said composition is an emulsion with an oil phase consisting of polysiloxanes, silicones, mineral oils or essential oils.
US2009/0117068 describes a solid composition applicable to a razor. Said composition comprises hydroxy acids, polyhydroxy acids, trichloroacetic acid.
Disadvantageously, said cosmetic compositions do not provide a
protection for the trichloroacetic acid which, upon contact with oxygen, can oxidize and modify its nature.
Another drawback is due to the fact that there is not a system which allows the use of the topical composition in complete safety even after opening a package which contains the same.
US2014/037561 describes compositions comprising trichloroacetic acid, which is stabilized with a mixture of chemical stabilizing agents in ratios from 0.1: 1 to 5: 1. In Example 5, it is stated that under the same conditions, after 90 days, while the TCA in aqueous solution alone degrades by 12.6%, when it is in the presence of a low percentage of stabilizing agents, it degrades on average by 4-5%, and when it is in the presence of a high percentage of stabilizing agents, it degrades on average by 2-3%. Therefore, the teaching is to increase the amount of chemical stabilizing agents with respect to the TCA, however without providing information about the trend of this degradation over 90 days, and certainly without having considered the impact on the tolerability of the composition on the skin.
The object of the present invention is therefore to obtain products for medical use, in particular for topical use, capable of maintaining constant over time the properties of all the components present in the products.
Another object is to obtain topical products capable of preserving the nature of trichloroacetic acid.
SUMMARY OF THE INVENTION
According to the invention, these objects are achieved by a biphasic topical product as described in claim 1.
In another aspect, the present invention relates to a method for preparing topical products capable of preserving the nature of trichloroacetic acid and preventing oxidation thereof, as described in claim 22.
BRIEF DESCRIPTION OF THE DRAWING
The characteristics and advantages of the present invention will
become more apparent from the following detailed description, the embodiments shown by way of non-limiting examples, and the accompanying drawing, wherein:
- Figure 1 shows the biphasic product of Example 1.
DETAILED DESCRIPTION OF THE INVENTION
The invention therefore relates to a biphasic topical product comprising a mixture of hydroxy acids, trichloroacetic acid and bioactive substances with non-exfoliating activity, wherein two phases are present, a hydrophilic phase and a lipophilic phase. Said lipophilic phase floats above the hydrophilic phase, so that the latter does not come into direct contact with the oxygen present in the atmosphere. In fact, as will be clear from the following Examples and as clearly illustrated in Figure 1, the biphasic product of the present invention has and maintains a clear-cut separation surface between the two phases immiscible with each other, since the product is free of emulsifying surfactants. In this sense, it has surprisingly been found that the lipophilic phase overlying the hydrophilic phase, wherein trichloroacetic acid (or TCA) is present, creates a physical barrier which isolates the hydrophilic phase, thus preventing the contact with the air and therefore, as said, with oxygen causing the oxidation of TCA. This allows overcoming the drawbacks associated with the emulsions of the prior art, which instead left the phase containing TCA inevitably exposed to air.
It follows that TCA, as well as the entire hydrophilic phase as a whole, is conserved for very long periods of time, even for a few years, without significant variations and above all without the use of stabilizers or chemical preservatives.
It should in fact be noted that reducing the use of stabilizers and chemical preservatives as much as possible ensures products which are much more natural and tolerable from the dermatological point of view. However, on the other hand, the absence of stabilizers and chemical preservatives makes natural products themselves more delicate than
"chemical" ones, and more subject to degradation.
The solution provided by the present invention is therefore particularly advantageous in that it allows eliminating the use of stabilizers and chemical preservatives without compromising the stability of the product, on the contrary obtaining a long and constant preservation capacity over time. The biphasic product of the present invention is therefore both highly tolerable by the skin, even in the case of subjects exposed to allergies, and extremely stable, as well as visually pleasing and commercially attractive.
The biphasic topical product of the invention therefore comprises a mixture of hydroxy acids, trichloroacetic acid and bioactive substances with non-exfoliating activity, wherein said topical product comprises a hydrophilic phase and a lipophilic phase, the biphasic topical product being free of emulsifying surfactants, and said bioactive substances with non- exfoliating activity comprise a mixture of vitamins and amino acids.
Preferably, the biphasic topical product is also free of stabilizers and preservatives.
This mixture of hydroxy acids, trichloroacetic acid and bioactive substances is present in the hydrophilic phase.
Said hydroxy acids may be alpha-hydroxy acids, beta-hydroxy acids, or polyhydroxy acids.
The alpha hydroxy acids are for example selected from tartaric acid, citric acid, glycolic acid, lactic acid, malic acid; the beta hydroxy acids are for example selected from hydroxybutyric acid and salicylic acid; the polyhydroxy acids are for example selected from lactobionic acid and gluconolactone.
The hydrophilic phase preferably comprises tartaric acid, citric acid, salicylic acid and lactobionic acid.
Tartaric acid is present in a final concentration of 2% to 15%, preferably 3% to 12%, even more preferably 4% to 10%. For the purposes of the present invention, "%" means "% by weight" based on the weight of the
phase wherein the ingredient is present.
Citric acid is present in a final concentration by weight of 0.3% to 5%, preferably 0.4% to 4%, even more preferably 0.5% to 3%.
Salicylic acid is present in a final concentration by weight of 0.5% to 14%, preferably 0.75% to 12%, even more preferably 1% to 10%.
Lactobionic acid is present in a final concentration by weight of 3% to 10%, preferably 4% to 13%, even more preferably 5% to 11%.
Trichloroacetic acid has a final concentration by weight of 5% to 60%, preferably 7% to 55%, even more preferably 9% to 50%.
The amino acids present in the hydrophilic phase are for example glycine, proline, hydroxy-proline and arginine. Said amino acids have a final concentration by weight of 0.01% to 12%, preferably 0.02% to 10%, even more preferably 0.03% to 10%.
The vitamins present in the hydrophilic phase have a final concentration by weight of 0.05% to 2%, preferably 0.06% to 1.5%, even more preferably 0.07% to 1%.
The vitamins present in the hydrophilic phase are riboflavin (Vitamin B2) and Vitamin C.
The hydrophilic phase also comprises gamma-amino-butyric acid (GABA) or dimethylaminoethanol with a contracturant and muscle relaxant action.
GABA is present in a final concentration of 1% to 10%, preferably 2% to 8%, even more preferably 3% to 7%.
Dimethylaminoethanol is present in a final concentration by weight of between 0.1% and 1%, preferably between 0.2% and 0.8%, even more preferably between 0.3% and 0.7%.
The hydrophilic phase may further comprise additives, pH adjusters, wetting agents, rheological modifiers, such as viscosizing and gelling agents. For example, it may comprise cationic polymers, cellulose derivatives of natural and semisynthetic extraction, silica and derivatives, EDTA,
potassium hydrogen phosphate, and sodium hydroxide.
Said hydrophilic phase further comprises water.
The lipophilic phase of the topical product comprises wetting and emollient agents and a heterogeneous mixture of heavy oils and saturated paraffinic hydrocarbons, such as petrolatum oil.
The emollient and wetting agent may be selected from isopropyl myristate and isopropyl palmitate, preferably isopropyl myristate, in a final concentration of 30% to 75%, preferably 40% to 70%.
Petrolatum oil is present in a final concentration of 20% to 50%, preferably 25% to 45%, even more preferably 30% to 40%.
In preferred embodiments, the lipophilic phase comprises petrolatum oil, isopropyl myristate, squalane, or a mixture thereof, more preferably a mixture thereof.
The biphasic topical product of the present invention may be prepared by methods which comprise the mixing of the individual components of each phase, and then the subsequent addition of the lipophilic phase to the hydrophilic phase. However, a method dedicated in particular to the preparation of the preferred embodiments of the product of the invention has been developed.
A second aspect of the present invention therefore comprises a method for preparing a product for topical use, preferably for external topical use.
Said method comprises the following steps:
- providing a certain quantity of wetting agents and water;
- preparing a mixture of salicylic acid, citric acid, tartaric acid, lactobionic acid and trichloroacetic acid;
- solubilizing the remaining components;
- preparing a solution of sodium hydroxide to adjust the pH of the above-mentioned mixture;
- proceeding with pH adjustment;
- providing adequate quantities of lipophilic components, which
should be mixed together;
- the two phases (portioned/added) form at the time of packaging when the two phases are added at successive times, the hydrophilic phase first and then the lipophilic phase.
Said method preferably comprises the following steps:
- providing a certain quantity of wetting agents and water;
- preparing the mixture by adding salicylic acid first, then the remaining acids in order from the least concentrated to the most concentrated: citric acid, tartaric acid, lactobionic acid and trichloroacetic acid;
- preparing a solution of sodium hydroxide to adjust the pH of the above-mentioned mixture;
- adjusting the pH up to a value of 1 to 2.5, with a tolerance of 0.5;
- solubilizing the remaining components in order from the least concentrated to the most concentrated;
- providing adequate quantities of lipophilic components, which should be mixed together;
- the two phases form at the time of packaging when the two phases are added at successive times, the hydrophilic phase first and then the lipophilic phase.
As mentioned, the main function of the lipophilic phase is to protect the trichloroacetic acid from oxidation, acting as a mechanical barrier against the oxygen present inside the final bottle where the product is portioned. The oxygen in contact with the preparation in the closed bottle would activate the oxidation process with browning (cleavage of the trichloroacetic acid, per se it does not darken, but splits) of the trichloroacetic acid and the relative conversion of the latter into degradation products which are harmful, highly irritating and allergenic to the dermis such as chloroform and formic acid.
For this reason, in the present invention, the lipophilic phase acts as a
protection mechanism, thus avoiding contact between the hydrophilic phase, containing the trichloroacetic acid, and the oxygen contained in the bottle even after stirring and mixing between the hydrophilic and lipophilic phase, as a microfilm of lipophilic phase remains constantly above the hydrophilic phase due to density difference and thus permanently protecting the compound from contact with oxygen, and thus preventing the oxidation of trichloroacetic acid, avoiding the conversion thereof into harmful substances for the skin.
The two phases may be of two different colors, which choice makes the product even more appealing from the commercial point of view and for the overall pleasantness, for example, yellow for the hydrophilic phase and blue for the lipophilic phase.
The second function of the lipophilic phase in addition to that of protecting trichloroacetic acid is to perform a filming, emollient and moisturizing activity on the skin, owing to its composition preferably obtained with: isopropyl-myristate, wetting and moisturizing with natural derivation from nutmeg; squalane with protective function of the skin, due to the ability to regenerate the lipid film which prevents aggression by external agents, and moisturizing, reducing the evaporation of water from the deeper epidermal layers and petrolatum oil which creates a protective film
(occlusive film), capable of decreasing trans-epidermal water loss.
The hydrophilic phase is characterized not only by trichloroacetic acid, but also preferably by an innovative mixture of alpha (tartaric acid, citric acid), beta (salicylic acid) and poly (lactobionic acid) hydroxy acids rich in hydroxyls, selected and dosed advantageously in the present invention, and which perform an additional direct hydration function in addition to the already known exfoliating one. Moreover, the synergy of trichloroacetic acid and salicylic acid, known as keratolytics, allows the penetration of the pool of amino acids, vitamins and bioactive substances present in the preparation. The amino acids present in the preparation, preferably glycine, proline,
hydroxyproline, arginine, lysine or mixtures thereof, play a stimulating action in the synthesis of collagen, being natural constituents, and activate capillary microcirculation by favoring the biostimulation processes.
It has been possible to introduce amino acids, for the first time in this type of treatment, advantageously exploiting the isoelectric equilibrium of the latter in acidic solution. Vitamin C acts as a catalyst for the formation of new collagen in synergy with amino acids. The hydrophilic phase also contains gamma amino butyric acid or dimethylaminoethanol with a decontracting and muscle relaxant action.
The present invention finally relates to the topical, preferably external topical use of the biphasic product in the dermatological and dermocosmetic treatment of the skin, in particular in skin peeling treatments.
It should be understood that all the possible combinations of the preferred aspects of the components of the two-phase product, its preparation and their uses are deemed to be described and therefore similarly preferred.
It should also be understood that all aspects identified as preferred and advantageous for the biphasic product and its components should be deemed as similarly preferred and advantageous also for the preparation and uses of the biphasic product itself.
The following examples are non-limiting embodiments of the present invention.
EXAMPLES
Example 1.
A biphasic topical product according to the present invention was prepared, having the following composition:
Trade name INCI Name wt %
Hydrophilic phase
EDTA Disodium EDTA 0.01
RIBOFLAVIN Riboflavin 0.1
SODIUM ASCORBATE Sodium ascorbate 2
GLYCINE Glycine 0.1
PROLINE Proline 0.1
HYDROXYPROLINE Hydroxyproline 0.1
SALICYLIC ACID Salicylic acid 3
POLYQUATERNIUM 10 Polyquaternium- 10 2.5
POTASSIUM HYDROGEN Potassium phosphate dibasic 1.5 PHOSPHATE
CITRIC ACID Citric acid 1
AMINOBUTYRIC ACID Aminobutyric acid 1
TARTARIC ACID Tartaric acid 5
LACTOBIONIC ACID Lactobionic acid 5
ARGININE Arginine 5
TRICHLOROACETIC ACID Trichloroacetic acid 35
SODIUM HYDROXIDE Sodium hydroxide 4
HYDROPHILIC YELLOW STAIN CI 19140 0.001
WATER AQUA Balance to 100%
Lipophilic phase
ISOPROPYL MYRISTATE Isopropyl myristate 40
PETROLATUM Petrolatum 39.999
SQUALANE Squalane 20
LIPOPHILIC BLUE STAIN CI 61565 0.001
The resulting biphasic topical product is shown in Figure 1, where it is clear that the underlying hydrophilic phase and the overlying lipophilic phase are evidently distinct from each other by a continuous separation surface.
Example 2.
A biphasic topical product according to the present invention was prepared, having the following composition:
Trade name INCI Name % by weight
Hydrophilic phase
EDTA Disodium EDTA 0.01
RIBOFLAVIN Riboflavin 0.1
SODIUM ASCORBATE Sodium ascorbate 2
GLYCINE Glycine 0.1
PROLINE Proline 0.1
HYDROXYPROLINE Hydroxyproline 0.1
SALICYLIC ACID Salicylic acid 3
POLYQUATERNIUM 10 Polyquaternium- 10 2.5
POTASSIUM HYDROGEN Potassium phosphate dibasic 1.5 PHOSPHATE
CITRIC ACID Citric acid 1
AMINOBUTYRIC ACID Aminobutyric acid 1
TARTARIC ACID Tartaric acid 5
LACTOBIONIC ACID Lactobionic acid 5
ARGININE Arginine 5
TRICHLOROACETIC ACID Trichloroacetic acid 50
SODIUM HYDROXIDE Sodium hydroxide 5.5
HYDROPHILIC YELLOW STAIN CI 19140 0.001
WATER AQUA Balance to 100%
Li] )ophilic phase
ISOPROPYL MYRISTATE Isopropyl myristate 40
PETROLATUM Petrolatum 39.999
SQUALANE Squalane 20
LIPOPHILIC BLUE STAIN CI 61565 0.001
Example 3.
A biphasic topical product according to the present invention was prepared, having the following composition:
Ingredient % m v
Hydrophilic phase
Trichloroacetic acid 50
Sodium hydroxide 5.6
Arginine 4.17
Lactobionic acid 4.17
Tartaric acid 4.17
Polyquaternium- 10 2.08
Salicylic acid 1.67
Sodium ascorbate 1.67
Potassium phosphate dibasic 1.67
Aminobutyric acid 0.83
Citric acid 0.83
Riboflavin 0.01
Hydroxyproline 0.01
Proline 0.01
Glycine 0.01
Disodium EDTA 0.01
CI 19140 0.001
Water 6.418
Lipophilic phase
Isopropyl myristate 6.67
Petrolatum 6.67
Squalane 3.33
CI 61565 0.001
Example 4.
Evaluation of stability
The product obtained in Example 3 was subjected to a test to verify its stability over time.
MATERIALS AND METHODS THERMOSTATS:
MEMMERT HPP260 - Memmert GmbH + Co.KG
• Uncontrolled room temperature (°C): 5°<T<25°
• Controlled temperature (°C): 20°
• Controlled temperature (°C): 25°
pH METER:
pH meter Basic 20 - CRISON INSTRUMENT, SA
VISCOSIMETER:
BROOKFIELD DV2T
MICROBIOLOGICAL ANALYSIS:
Seeding by plate inclusion:
AEROBIC MESOPHILIC BACTERIAL COUNT CFU/G method according to UNI EN ISO 21149:20170 (briefly "CBT")
PARAMETERS EVALUATED
Time correspondence:
• 12 weeks accelerated = 1 year
• 24 weeks accelerated = 2 years
Specifications Storage conditions and frequency of analysis
Parameter Reference 5°<T<25 60% ±5% (Weeks)
12 weeks 24 weeks
Appearance, color, Compliant with std. Blue- Yellow Blue- Yellow smell compliant compliant pH 1.5+0.5 1.51 1.53
Viscosity 1000-2000 SP 6-20 RPM 1546 1534
CBT < 100 cfu/g < 100 cfu/g < 100 cfu/g
Specifications Storage conditions and frequency of analysis
Parameter Reference T 20° + 2/60% +5% (Weeks)
12 weeks 24 weeks
Appearance, color, Compliant with std. Blue- Yellow Blue- Yellow smell compliant compliant pH 1.5+0.5 1.52 1.56
Viscosity 1000-2000 SP 6-20 RPM 1541 1552
CBT < 100 cfu/g < 100 cfu/g < 100 cfu/g
Specifications Applicable storage conditions and frequency of analysis
Parameter Reference T 25° + 2/60% +5% (Weeks)
12 weeks 24 weeks
Appearance, color, Compliant with std. Blue- Yellow Blue- Yellow smell compliant compliant pH 1.5+0.5 1.53 1.58
Viscosity 1000-2000 SP 6-20 RPM 1539 1545
CBT < 100 cfu/g < 100 cfu/g < 100 cfu/g
The above results clearly demonstrate the high stability of the product according to the invention, even under conditions of accelerated aging, for considerably prolonged periods of time, i.e. up to 2 years, without significant variations.
Claims (23)
1. A biphasic topical product comprising a mixture of hydroxy acids, trichloroacetic acid and bioactive substances with non-exfoliating activity, characterized in that said biphasic topical product comprises a hydrophilic phase and a lipophilic phase floating on said hydrophilic phase, said bioactive substances with non-exfoliating activity comprising a mixture of vitamins and amino acids.
2. The topical product according to claim 1, wherein the hydrophilic phase comprises a mixture of alpha hydroxy acids, beta hydroxy acids and polyhydroxy acids.
3. The topical product according to claim 2, wherein the alpha hydroxy acids are selected from tartaric acid, citric acid, glycolic acid, lactic acid, malic acid; the beta hydroxy acids are selected from hydroxybutyric acid and salicylic acid; the polyhydroxy acids are selected from lactobionic acid and gluconolactone.
4. The topical product according to claims 2 and 3, wherein the hydrophilic phase comprises tartaric acid, citric acid, salicylic acid and lactobionic acid.
5. The topical product according to any one of the preceding claims, wherein the hydrophilic phase comprises gamma-amino-butyric acid
(GAB A) or dimethylaminoethanol.
6. The topical product according to any one of the preceding claims, wherein the amino acids present in the hydrophilic phase are selected from glycine, proline, hydroxy-proline, arginine and lysine and the vitamins are riboflavin and vitamin C.
7. The topical product according to claims 3 and 4, wherein the tartaric acid is present at a final concentration by weight of 2% to 15%, the citric acid is present at a final concentration by weight of 0.3% to 5%, the salicylic acid is present at a final concentration by weight of 0.5% to 14%, the lactobionic acid is present at a final concentration by weight of 3% to 10%,
and trichloroacetic acid has a final concentration by weight of 5% to 60%.
8. The topical product according to claim 7, wherein the tartaric acid is present at a final concentration by weight of 3% to 12%, the citric acid is present at a final concentration by weight of 0.4% to 4%, the salicylic acid is present at a final concentration by weight of 0.75% to 12%, the lactobionic acid is present at a final concentration by weight of 4% to 13%, and trichloroacetic acid has a final concentration by weight of 7% to 55%.
9. The topical product according to claim 8, wherein the tartaric acid is present at a final concentration by weight of 4% to 10%, the citric acid is present at a final concentration by weight of 0.5% to 3%, the salicylic acid is present at a final concentration by weight of 1% to 10%, the lactobionic acid is present at a final concentration by weight of 5% to 11%, and trichloroacetic acid has a final concentration by weight of 9% to 50%.
10. The topical product according to claim 6, wherein the amino acids have a final concentration by weight of 0.01% to 12%, and the vitamins have a final concentration by weight of 0.05% to 2%.
11. The topical product according to claim 10, wherein the amino acids have a final concentration by weight of 0.02% to 10%, and the vitamins have a final concentration by weight of 0.06% to 1.5%.
12. The topical product according to claim 11, wherein the amino acids have a final concentration by weight of 0.03% to 10%, and the vitamins have a final concentration by weight of 0.07% to 1%.
13. The topical product according to claim 5, wherein the GABA is present at a final concentration by weight of 1% to 10%, or dimethylaminoethanol is present at a final concentration by weight of 0.1% to 1%.
14. The topical product according to claim 13, wherein the GABA is present at a final concentration by weight of 2% to 8%, or dimethylaminoethanol is present at a final concentration by weight of 0.2% to 0.8%.
15. The topical product according to claim 14, wherein the GABA is present at a final concentration by weight of 3% to 7%, or dimethylaminoethanol is present at a final concentration by weight of 0.3% to 0.7%.
16. The topical product according to any one of the preceding claims, wherein the hydrophilic phase comprises additives, preservatives, pH adjusters, wetting agents, rheological modifiers, such as viscosifying and gelling agents.
17. The topical product according to claim 16, comprising cationic polymers, natural and semi- synthetic extraction cellulose derivatives, silica and derivatives, EDTA, potassium hydrogen phosphate, glycerol, wetting agents and sodium hydroxide.
18. The topical product according to any one of the preceding claims, wherein the lipophilic phase of the topical product comprises wetting and emollient agents and petrolatum oil.
19. The topical product according to claim 18, wherein the wetting and emollient agents are selected from isopropyl-myristate and isopropyl- palmitate.
20. The topical product according to claim 19, wherein isopropyl- myristate is at a final concentration of 30% to 75%, and petrolatum oil has a concentration of 20% to 50%.
21. The topical product according to claim 20, wherein isopropyl- myristate is at a final concentration of 40% to 70%, and petrolatum oil has a concentration of 25% to 45%.
22. A method for preparing a biphasic topical product, comprising the steps of:
- providing wetting agents and water;
- preparing a mixture of salicylic acid, citric acid, tartaric acid, lactobionic acid and trichloroacetic acid;
- preparing a solution of sodium hydroxide to adjust the pH of said
mixture;
- adjusting the pH of the mixture;
- solubilizing the remaining components;
- providing lipophilic components and mixing them.
23. The method according to claim 22, further comprising the steps of:
- preparing the mixture by adding salicylic acid first, then the remaining acids in order from the least concentrated to the most concentrated: citric acid, tartaric acid, lactobionic acid and trichloroacetic acid;
- adjusting the pH of the mixture up to a value between 1 and 2.5 with a tolerance of 0.5.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102017000104536 | 2017-09-19 | ||
IT102017000104536A IT201700104536A1 (en) | 2017-09-19 | 2017-09-19 | Topical products with two-phase system |
PCT/IB2018/057131 WO2019058249A1 (en) | 2017-09-19 | 2018-09-18 | Topical products with a biphasic system |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2018335555A1 AU2018335555A1 (en) | 2020-03-05 |
AU2018335555A9 true AU2018335555A9 (en) | 2023-09-07 |
AU2018335555B2 AU2018335555B2 (en) | 2024-04-04 |
Family
ID=61006168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018335555A Active AU2018335555B2 (en) | 2017-09-19 | 2018-09-18 | Topical products with a biphasic system |
Country Status (17)
Country | Link |
---|---|
US (1) | US11504307B2 (en) |
EP (1) | EP3694477B1 (en) |
JP (1) | JP7135075B2 (en) |
KR (1) | KR20200055069A (en) |
CN (1) | CN111148502B (en) |
AU (1) | AU2018335555B2 (en) |
BR (1) | BR112020005491B1 (en) |
CA (1) | CA3073792A1 (en) |
DK (1) | DK3694477T3 (en) |
ES (1) | ES2905873T3 (en) |
IT (1) | IT201700104536A1 (en) |
MA (1) | MA50357A (en) |
MX (1) | MX2020002957A (en) |
PL (1) | PL3694477T3 (en) |
PT (1) | PT3694477T (en) |
RU (1) | RU2764769C2 (en) |
WO (1) | WO2019058249A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201700104536A1 (en) | 2017-09-19 | 2019-03-19 | Cmed Aesthetics Srl | Topical products with two-phase system |
WO2020260199A1 (en) * | 2019-06-24 | 2020-12-30 | Rossana Castellana | Formulations for odontological and dermatological use containing trichloroacetate salts and hydroxyacids |
IT201900020526A1 (en) * | 2019-11-07 | 2021-05-07 | Francesco Leva | Three-phase emulsifiable formulation and its therapeutic and / or cosmetological uses |
WO2022131141A1 (en) * | 2020-12-14 | 2022-06-23 | L'oreal | Multi-phase composition comprising alpha hydroxy acid |
FR3118872B1 (en) * | 2021-01-15 | 2024-02-02 | Oreal | MULTIPHASIC COMPOSITION COMPRISING AN ALPHA-HYDROXYACID |
FR3117834B1 (en) * | 2020-12-17 | 2023-11-10 | Oreal | Two-phase cosmetic composition comprising an amino acid and two specific acids |
AU2022274611A1 (en) | 2021-05-13 | 2023-11-16 | Colgate-Palmolive Company | Personal care formulations |
KR102648939B1 (en) * | 2023-08-18 | 2024-03-19 | 한국콜마주식회사 | Cosmetic composition comprising high amaount of acid |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU83173A1 (en) * | 1981-02-27 | 1981-06-05 | Oreal | NOVEL COSMETIC COMPOSITIONS FOR THE TREATMENT OF HAIR AND SKIN CONTAINING POWDER RESULTING FROM THE SPRAYING OF AT LEAST ONE PLANT AND A COHESION AGENT |
DE4100490C1 (en) | 1991-01-10 | 1992-03-05 | Goldwell Ag, 6100 Darmstadt, De | |
DE9320586U1 (en) | 1993-10-11 | 1994-10-13 | Hgb Pharma Service Gmbh | Topical formulation of a solubilized ginkgo biloba extract |
FR2751537B1 (en) * | 1996-07-26 | 2004-04-16 | Oreal | USE OF HONEY AS A KERATOLYTIC AGENT, PARTICULARLY FOR IMPROVING THE RADIANCE OF THE SKIN AND TREATING WRINKLES |
BR9803596A (en) | 1997-09-23 | 2000-04-25 | Pfizer Prod Inc | Derivatives of resorcinol. |
JP2000186036A (en) * | 1998-10-16 | 2000-07-04 | Showa Denko Kk | Chemical peeling agent composition |
HN2000000033A (en) | 1999-03-22 | 2001-02-02 | Pfizer Prod Inc | RESORCINOL COMPOSITION |
AU3996799A (en) * | 1999-05-18 | 2000-12-05 | Klein, Marvin E. | Alpha amino acid composition and method for the treatment of skin |
JP3970492B2 (en) * | 1999-12-14 | 2007-09-05 | コスモ石油株式会社 | Peeling composition |
RU2195921C2 (en) * | 2000-07-27 | 2003-01-10 | Научно-производственная фирма "Аквазинэль" | Cream from solar burns |
WO2002049656A1 (en) * | 2000-12-19 | 2002-06-27 | Kabushiki Kaisha Yakult Honsha | External skin preparations and process for producing the same |
KR20040021589A (en) * | 2001-03-13 | 2004-03-10 | 아지노모토 가부시키가이샤 | Cosmetics or external preparations for skin |
US7477940B2 (en) | 2003-06-30 | 2009-01-13 | J&J Consumer Companies, Inc. | Methods of administering an active agent to a human barrier membrane with galvanic generated electricity |
FR2859626B1 (en) | 2003-09-12 | 2006-01-27 | Oreal | BIPHASE COMPOSITION AND USES IN THE COSMETIC FIELD |
US7514092B2 (en) * | 2004-12-22 | 2009-04-07 | Avon Products, Inc. | Compositions and methods of their use for improving the condition and appearance of skin |
CA2622637A1 (en) | 2005-09-16 | 2007-03-22 | Reckitt Benckiser (Uk) Limited | Improvements in or relatimg to cosmetic compositions |
GB0520931D0 (en) | 2005-10-14 | 2005-11-23 | Reckitt Benckiser Uk Ltd | Improvements in or relating to compositions |
ITUD20050211A1 (en) | 2005-12-13 | 2007-06-14 | Rossana Castellana | PRODUCT FOR THE TREATMENT OF THE RELATIVE SKIN PROCEDURE OF PREPARATION |
DE102006020382A1 (en) * | 2006-04-28 | 2007-10-31 | Henkel Kgaa | Cosmetic oil-in-water emulsion, useful e.g. to treat skin, comprises oil or fat phase comprising a component e.g. branched saturated alkanol, water, a cosmetically active substance e.g. monomer and a polysaccharide |
FR2909279B1 (en) * | 2006-11-30 | 2014-06-13 | Oreal | PEELING PROCESS BASED ON CATIONIC MICROGEL |
JP2008231010A (en) | 2007-03-20 | 2008-10-02 | Shiseido Co Ltd | External preparation for skin |
GB2451224A (en) * | 2007-05-09 | 2009-01-28 | Frances Prenna Jones | Cosmetic composition comprising an exfoliant, astringent, antioxidant and moisturiser |
US8568749B2 (en) | 2009-04-02 | 2013-10-29 | Sesvalia Usa, Llc | Systems and methods for skin rejuvenation |
US8460687B1 (en) * | 2009-07-07 | 2013-06-11 | Cosmoceutical Research Center | Peeling compositions |
US8906432B2 (en) * | 2009-10-02 | 2014-12-09 | Johnson & Johnson Consumer Companies, Inc. | Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter |
WO2012105982A1 (en) * | 2011-02-03 | 2012-08-09 | Kulesza John E | Skin renewal enhancer |
DE102011110909A1 (en) * | 2011-08-18 | 2013-02-21 | Paul Hartmann Ag | Compositions having a skin barrier enhancing drug combination |
US10639252B2 (en) * | 2011-09-23 | 2020-05-05 | Allergan, Inc. | Compositions for skin exfoliation and use thereof |
WO2013091894A2 (en) * | 2011-12-21 | 2013-06-27 | Flavin Dana | Topical compositions |
PL224184B1 (en) | 2012-02-22 | 2016-11-30 | Pulanna Spółka Z Ograniczoną Odpowiedzialnością | Biphasic natural cosmetics |
JP2017515861A (en) | 2014-05-16 | 2017-06-15 | レスターシー エルエルシイRestorsea, Llc | Biphasic cosmetics |
EP3006016A1 (en) * | 2014-10-06 | 2016-04-13 | Medical Brands Research B.V. | Dermatological kit comprising compositions based on Hibiscus flower and Buriti oil |
US20160250130A1 (en) * | 2014-12-18 | 2016-09-01 | The Ionto Team, S.L. | Cosmetic formulation and device for the treatment of deep wrinkles of the skin by means of iontophoresis |
IT201700104536A1 (en) | 2017-09-19 | 2019-03-19 | Cmed Aesthetics Srl | Topical products with two-phase system |
-
2017
- 2017-09-19 IT IT102017000104536A patent/IT201700104536A1/en unknown
-
2018
- 2018-09-18 MX MX2020002957A patent/MX2020002957A/en unknown
- 2018-09-18 WO PCT/IB2018/057131 patent/WO2019058249A1/en unknown
- 2018-09-18 PT PT187868609T patent/PT3694477T/en unknown
- 2018-09-18 BR BR112020005491-7A patent/BR112020005491B1/en active IP Right Grant
- 2018-09-18 MA MA050357A patent/MA50357A/en unknown
- 2018-09-18 EP EP18786860.9A patent/EP3694477B1/en active Active
- 2018-09-18 PL PL18786860T patent/PL3694477T3/en unknown
- 2018-09-18 US US16/644,975 patent/US11504307B2/en active Active
- 2018-09-18 DK DK18786860.9T patent/DK3694477T3/en active
- 2018-09-18 ES ES18786860T patent/ES2905873T3/en active Active
- 2018-09-18 JP JP2020515654A patent/JP7135075B2/en active Active
- 2018-09-18 AU AU2018335555A patent/AU2018335555B2/en active Active
- 2018-09-18 CA CA3073792A patent/CA3073792A1/en active Pending
- 2018-09-18 CN CN201880061003.2A patent/CN111148502B/en active Active
- 2018-09-18 RU RU2020113711A patent/RU2764769C2/en active
- 2018-09-18 KR KR1020207011247A patent/KR20200055069A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2020113711A3 (en) | 2021-10-20 |
EP3694477B1 (en) | 2021-12-01 |
BR112020005491A2 (en) | 2020-09-24 |
AU2018335555B2 (en) | 2024-04-04 |
IT201700104536A1 (en) | 2019-03-19 |
KR20200055069A (en) | 2020-05-20 |
CN111148502A (en) | 2020-05-12 |
AU2018335555A1 (en) | 2020-03-05 |
BR112020005491B1 (en) | 2023-10-03 |
MX2020002957A (en) | 2022-05-26 |
PT3694477T (en) | 2022-02-08 |
ES2905873T3 (en) | 2022-04-12 |
RU2020113711A (en) | 2021-10-20 |
PL3694477T3 (en) | 2022-04-25 |
US11504307B2 (en) | 2022-11-22 |
JP2020534282A (en) | 2020-11-26 |
JP7135075B2 (en) | 2022-09-12 |
US20200276090A1 (en) | 2020-09-03 |
EP3694477A1 (en) | 2020-08-19 |
CN111148502B (en) | 2023-04-28 |
DK3694477T3 (en) | 2022-03-07 |
MA50357A (en) | 2020-08-19 |
RU2764769C2 (en) | 2022-01-21 |
WO2019058249A1 (en) | 2019-03-28 |
CA3073792A1 (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018335555B2 (en) | Topical products with a biphasic system | |
JP2651366B2 (en) | Cosmetic and / or dermatological composition having a hydrophilic carrier and vitamin C mixed immediately before use | |
JP2001513076A (en) | Stabilized ascorbyl composition | |
JP5836128B2 (en) | Compositions and methods for treating hyperpigmentation | |
CN109846740B (en) | Skin care composition and preparation method and application thereof | |
KR100358210B1 (en) | Cosmetic composition comprising orange extract with anti-radical activity | |
KR20060015597A (en) | Cosmetic product containing mineral water for remineralising and rejuvenating the skin | |
JP2001288032A (en) | Active oxygen-eliminating agent and skin cosmetic for preventing aging | |
CN105496822A (en) | Tartaric acid skin lotion and preparation method thereof | |
KR20090078082A (en) | The skin beautifing cosmetic composition containing vitamin c and the extract of opuntia ficus-indica l. var. saboten makino flowers | |
KR100472919B1 (en) | Water soluble whitening composition and cosmetic composition for whitening skin comprising the same | |
KR100205499B1 (en) | Basic cosmetic compositions having wrinkle-suppressing effect without skin-irritation | |
CN115605176A (en) | Composition for preparing an emulsifiable three-phase formulation and kit using the same | |
US9393182B2 (en) | Anti-aging product | |
CN112773740A (en) | Firming and wrinkle-removing essence and preparation method thereof | |
CN114533584B (en) | Collagenase anti-wrinkle face cream | |
JP3333428B2 (en) | External preparation for skin | |
JP2004168725A (en) | External aqueous composition for skin | |
KR20160143017A (en) | cosmetis composition having peptide | |
JP2018177691A (en) | Melanogenesis inhibitor | |
KR102050861B1 (en) | Stabilizing reagent for tattoo sticker | |
JP2006249000A (en) | Bleaching cosmetic and bleaching cosmetic set | |
BR102019005743A2 (en) | COSMETIC COMPOSITION, USE OF A COSMETIC COMPOSITION AND THE PROCESS OF MANUFACTURING A COSMETIC COMPOSITION | |
TW202000177A (en) | Slow-releasing skincare composite structure with granulated essential oil carrier | |
FR3076211A1 (en) | USE OF CYCLOALKYL DERIVATIVES (HERERO) AS DEODORANT AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SREP | Specification republished | ||
HB | Alteration of name in register |
Owner name: CMED AESTHETICS S.P.A. Free format text: FORMER NAME(S): CMED AESTHETICS S.R.L. |